ArticleBreast cancer research and treatment2012

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Daniel L Hertz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.